Todd Brady
Chief Executive Officer at ALDEYRA THERAPEUTICS, INC.
Net worth: 4 M $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lawrence Kenyon | M | 58 | 9 years | |
| Matthew D'Onofrio | M | 54 | 17 years | |
| Richard Douglas | M | 71 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 years |
| Cam Garner | M | 75 | 17 years | |
| Bruce Greenberg | M | 56 | 5 years | |
| Neil Brewis | M | 57 | 4 years | |
| Nancy Miller-Rich | F | 65 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 4 years |
| Ben Bronstein | M | 74 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 14 years |
| Tuomas R. Holmberg | M | - |
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 19 years |
| Jesse I. Treu | M | 76 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 9 years |
| Gary Phillips | M | 58 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 15 years |
| Martin Joyce | M | 70 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 11 years |
| Vickie Reed | F | 62 | 3 years | |
| Malcolm Hill | M | 67 | 17 years | |
| Yazan Haddadin | M | 48 | 7 years | |
| Kenneth Widder | M | 71 | 17 years | |
| Michael Timothy Cooke | M | 65 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 15 years |
| Neal Walker | M | 54 | 11 years | |
| Faisal Ghiath Munir Sukhtian | M | 39 | 7 years | |
| Dean Eliott | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 years |
| James A. Gow | M | - | 4 years | |
| Kurt Hilzinger | M | 63 | 9 years | |
| Kelly Mizer | M | - | 3 years | |
| Neil Walker | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | - |
| John P. Hennessey | M | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 15 years |
| Brian K. Adams | M | - |
Southeast BIO
| - |
| James Sandy | M | - | 2 years | |
| Gregory Duncan | M | 59 |
Southeast BIO
| - |
| Stephen Machatha | M | 47 | 3 years | |
| Karen Zaderej | F | 62 |
Southeast BIO
| - |
| Kyp Sirinakis | F | - |
Southeast BIO
| 6 years |
| John E. Edwards | M | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 19 years |
| Geeta S. Vemuri | M | - |
Southeast BIO
| - |
| Kenneth R. Tindall | M | - |
Southeast BIO
| 14 years |
| Marilyn Carlson | M | 76 | 11 years | |
| Garheng Kong | M | 49 |
Southeast BIO
| - |
| Jan P. Turek | M | - |
Southeast BIO
| - |
| Susan B. Washer | F | 63 |
Southeast BIO
| - |
| Evgeny Zaytsev | M | 56 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | - |
| Mike Gutch | M | 58 |
Southeast BIO
| - |
| Russell Medford | M | 69 |
Southeast BIO
| - |
| R. Gordon Douglas | M | 89 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | - |
| Douglas Reed | M | 70 |
Southeast BIO
| 15 years |
| William D. Kirkland | M | 60 |
Southeast BIO
| - |
| Caitlin Pazzano | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Gonyer | M | 60 | 17 years | |
| Darlene M. Deptula-Hicks | F | 66 | 3 years | |
| Stephen Tulipano | M | 65 | 4 years | |
| Fred M. Haney | M | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 5 years |
| Eliot Forster | M | 58 | 5 years | |
| Scott Glenn | M | 73 | 12 years | |
| David Arkowitz | M | 62 | 3 years | |
| Chris P. Fuller | M | - |
Dartmouth College
| 7 years |
| Joshua Reed | M | 51 | 4 years | |
| Albert Dyrness | M | 61 | 2 years | |
| Joe Thomas | M | - | 2 years | |
| Robin Hoke | F | - | 2 years | |
| Pamela Klein | M | 63 | 3 years | |
| Nessan Bermingham | M | 51 | 3 years | |
| Edward Benz | M | 78 | 4 years | |
| Geoff Race | M | 63 | 4 years | |
| Patrick Johan Hendrik Krol | M | 60 | 3 years | |
| C. Boyd Clarke | M | 74 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 5 years |
| Ann Rhoads | F | 58 | 8 years | |
| Jeffrey S. Halpern | M | 79 |
Dartmouth College
| 7 years |
| Mars Jonathan Bishop | M | - |
Dartmouth College
| 4 years |
| Steven Kahl | M | - |
Dartmouth College
| 4 years |
| David Stephen Lynch | M | - |
Dartmouth College
| 4 years |
| Eric Bjorkman | M | - |
Dartmouth College
| 4 years |
| Bruno Yang | M | - |
Dartmouth College
| 4 years |
| Megan Hammond | F | 55 |
Dartmouth College
| 4 years |
| Duncan MacLean | M | - |
Dartmouth College
| 4 years |
| Christine Vanden Beukel | F | - |
Dartmouth College
| 4 years |
| Scott Edward Dudgeon | M | - |
Dartmouth College
| 4 years |
| James Meneely | M | - |
Dartmouth College
| 4 years |
| Joshua Jewett | M | 54 |
Dartmouth College
| 4 years |
| Richie Graham | - | - |
Dartmouth College
| - |
| Carter Strickland | M | - |
Dartmouth College
| 4 years |
| John Parker | M | - |
Dartmouth College
| 4 years |
| Catherine Muller | F | - |
Dartmouth College
| 3 years |
| John Nagel | M | - |
Dartmouth College
| 4 years |
| Brian Schmidt | M | - |
Dartmouth College
| 4 years |
| Jim Barton | M | - |
Dartmouth College
| 4 years |
| J. Parker Davis | M | - |
Dartmouth College
| 4 years |
| Stephen V. McKenna | M | 55 |
Dartmouth College
| 4 years |
| Peter B. Evans | M | - |
Dartmouth College
| 4 years |
| James Terry White | M | - |
Dartmouth College
| 4 years |
| John C. Rich | M | - |
Dartmouth College
| 4 years |
| Brian J. Buenneke | M | - |
Dartmouth College
| 4 years |
| Red Barrett | M | - |
Dartmouth College
| 2 years |
| Dana Schmaltz | M | 57 |
Dartmouth College
| 4 years |
| David Shirreffs | M | - |
Dartmouth College
| 4 years |
| Douglas T. Sheehy | M | 57 |
Dartmouth College
| 4 years |
| Kernan V. Oberting | M | 54 |
Dartmouth College
| 4 years |
| Mark Mader | M | 53 |
Dartmouth College
| 4 years |
| Harry C. Midgley | M | - |
Dartmouth College
| 4 years |
| Ara Lovitt | M | - |
Dartmouth College
| 4 years |
| Bryan Roberts | M | 57 |
Dartmouth College
| 4 years |
| Thomas Fisher | M | - |
Dartmouth College
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 89 | 89.90% |
| United Kingdom | 10 | 10.10% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Todd Brady
- Personal Network
